IN2012DN03209A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03209A
IN2012DN03209A IN3209DEN2012A IN2012DN03209A IN 2012DN03209 A IN2012DN03209 A IN 2012DN03209A IN 3209DEN2012 A IN3209DEN2012 A IN 3209DEN2012A IN 2012DN03209 A IN2012DN03209 A IN 2012DN03209A
Authority
IN
India
Prior art keywords
virus
particles
subjects
fusion protein
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Vidadi Yusibov
Christine E Farrance
Konstantin A Musiychuk
Vadim Mett
Valentina Mett
Original Assignee
Fraunhofer Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Usa Inc filed Critical Fraunhofer Usa Inc
Publication of IN2012DN03209A publication Critical patent/IN2012DN03209A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
IN3209DEN2012 2009-09-18 2010-09-16 IN2012DN03209A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24377409P 2009-09-18 2009-09-18
US34806910P 2010-05-25 2010-05-25
PCT/US2010/049089 WO2011035004A1 (en) 2009-09-18 2010-09-16 Virus like particles comprising target proteins fused to plant viral coat proteins

Publications (1)

Publication Number Publication Date
IN2012DN03209A true IN2012DN03209A (enExample) 2015-10-23

Family

ID=43413029

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3209DEN2012 IN2012DN03209A (enExample) 2009-09-18 2010-09-16

Country Status (9)

Country Link
US (1) US20120219579A1 (enExample)
EP (1) EP2477650B8 (enExample)
CN (1) CN102695524B (enExample)
BR (1) BR112012005703A2 (enExample)
CA (1) CA2774640C (enExample)
ES (1) ES2752323T3 (enExample)
IN (1) IN2012DN03209A (enExample)
RU (1) RU2571223C2 (enExample)
WO (1) WO2011035004A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102181258B1 (ko) 2012-02-16 2020-11-20 브이엘피 테라퓨틱스 엘엘씨 바이러스 유사 입자 조성물
CA2864733C (en) * 2012-03-22 2018-09-18 Fraunhofer Usa, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
KR102494564B1 (ko) * 2013-06-03 2023-01-31 브이엘피 테라퓨틱스 인코포레이티드 말라리아 백신
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
EP3113801B1 (en) 2014-03-03 2020-10-07 Albert Einstein College of Medicine Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
MX383330B (es) 2014-09-11 2025-03-13 Vlp Therapeutics Inc Particula tipo virus de flavivirus.
WO2017081082A2 (en) * 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
WO2018089814A1 (en) * 2016-11-11 2018-05-17 Fraunhofer Usa, Inc. Covalently fused viral coat proteins for the display of target molecules
CN106986943B (zh) * 2017-02-28 2020-12-25 国药中生生物技术研究院有限公司 一种包含北极地松鼠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
AU2018388071B2 (en) 2017-12-20 2025-02-06 Vlp Therapeutics, Inc. Alphavirus replicon particle
CN115867658A (zh) 2020-04-17 2023-03-28 Vlp治疗公司 冠状病毒疫苗
MX2022013638A (es) 2020-04-30 2023-01-24 Vlp Therapeutics Inc Inmunoterapia con citocina.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
WO2005086667A2 (en) * 2004-02-27 2005-09-22 The Dow Chemical Company High efficiency peptide production in plant cells
CA2615658A1 (en) * 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
MX2008007005A (es) * 2005-12-02 2009-03-04 Dow Global Technologies Inc Particulas de virus de planta nuevos y metodos de inactivacion de estos.
WO2008089569A1 (en) * 2007-01-26 2008-07-31 Folia Biotech Inc. Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
EP3539567A1 (en) * 2007-07-02 2019-09-18 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)

Also Published As

Publication number Publication date
ES2752323T3 (es) 2020-04-06
WO2011035004A1 (en) 2011-03-24
CN102695524B (zh) 2014-07-09
EP2477650A1 (en) 2012-07-25
RU2571223C2 (ru) 2015-12-20
CA2774640C (en) 2019-11-26
CN102695524A (zh) 2012-09-26
RU2012114483A (ru) 2013-10-27
CA2774640A1 (en) 2011-03-24
WO2011035004A9 (en) 2019-01-24
EP2477650B1 (en) 2019-09-04
US20120219579A1 (en) 2012-08-30
BR112012005703A2 (pt) 2020-09-15
EP2477650B8 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
IN2012DN03209A (enExample)
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
ZA201109444B (en) Vaccines against herpes simplex virus type 2:compositions and methods for eliciting an immune response
SI2614140T1 (sl) Celične linije pridobljene iz MDCK prilagojene kulturi brez seruma in kulturi suspenzije in postopek priprave cepiva proti virusu z uporabo teh celic
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
JP2011136997A5 (enExample)
IL213572A0 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response aganist antigens in replication deficient recombinant virus vaccines
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
WO2010019262A3 (en) Polyvalent vaccine
WO2013022808A3 (en) Immunogenic protein conjugates and methods for making and using the same
CA2863949A1 (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
WO2012103496A3 (en) Expression of soluble viral fusion glycoproteins in mammalian cells
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
WO2009115917A3 (en) Improvements in preparation of influenza virus vaccine antigens
MX2014001626A (es) Preservacion asistida con vacio de productos biologicos, en particular de vacunas.
HK1250662A1 (zh) 用於治疗癌症的免疫原性融合蛋白
WO2012047267A3 (en) Polyvalent immunogen
WO2011100508A3 (en) Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2012118559A3 (en) Tetravalent and mixed head bivalent dengue vaccine
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
HK1212708A1 (zh) H1n1流感的計算優化的寬反應性抗原
MX2014004537A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles